3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
8
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
8
Other hematologic neoplasm
8
Lymphoid
3
Myeloid
1
Conditions
Myelodysplastic Syndromes
323
Leukemia, Myeloid, Acute
276
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
244
Leukemia
116
Myeloproliferative Disorders
106
Primary Myelofibrosis
100
Precursor Cell Lymphoblastic Leukemia-Lymphoma
100
Leukemia, Myelomonocytic, Chronic
78
Polycythemia Vera
74
Hematologic Neoplasms
67
Multiple Myeloma
50
Neoplasms
41
Lymphoma, Non-Hodgkin
40
Thrombocythemia, Essential
39
Hematologic Diseases
38
Leukemia, Lymphocytic, Chronic, B-Cell
37
Recurrence
35
Lymphoma
32
Leukemia, Myeloid, Chronic-Phase
31
Mastocytosis, Systemic
26
Bone Marrow Diseases
25
Leukemia, Myeloid
23
Blast Crisis
23
Anemia, Refractory, with Excess of Blasts
23
Hodgkin Disease
21
Bronchiolitis Obliterans Syndrome
16
Mastocytosis
15
Philadelphia Chromosome
14
Leukemia, Mast-Cell
13
Graft vs Host Disease
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Plasma Cell
×
Myeloid
×
Clear all
NCT07523555
2026-04-13
ADAPT-HEM
Beijing Biotech
Phase 1/2
Recruiting
96 enrolled